| Identification | More | [Name]
2-(2-Bromoethoxy)anisole | [CAS]
4463-59-6 | [Synonyms]
2-(2-BROMOETHOXY)-1-METHOXYBENZENE
2-(2-BROMOETHOXY)ANISOLE
2-(2-BROMOETHOXY)-METHOXYBENZENE
2-(2'-METHOXYPHENOXY)-ETHYL BROMIDE
AKOS BC-2659
TIMTEC-BB SBB008602
1-(2-Bromethoxy)-2-methoxy-benzol
2-(2-BROMOETHOXY)ANISOLE 98% | [EINECS(EC#)]
402-010-4 | [Molecular Formula]
C9H11BrO2 | [MDL Number]
MFCD00017892 | [Molecular Weight]
231.09 | [MOL File]
4463-59-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
43-45 °C(Solv: ethanol (64-17-5)) | [Boiling point ]
135-140 °C(Press: 7 Torr) | [density ]
1.382±0.06 g/cm3(Predicted) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
Pale Beige | [CAS DataBase Reference]
4463-59-6(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed.
R52/53:Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment . | [Safety Statements ]
S22:Do not breathe dust .
S61:Avoid release to the environment. Refer to special instructions safety data sheet . | [HazardClass ]
IRRITANT |
| Hazard Information | Back Directory | [Uses]
2-(2-Bromoethoxy)anisole can be used as HIV inhibitors. | [Synthesis]
GENERAL METHOD: 1,2-Dibromoethane (0.02 mol) was dissolved in 40 mL of acetone and added slowly and dropwise to a 30 mL solution of acetone containing guaiacol (0.08 mol) and K2CO3 (0.04 mol). Subsequently, a catalytic amount of KI (0.3 mmol) was added and the reaction mixture was stirred at 60 °C for 24-72 hours. Upon completion of the reaction, the inorganic residue was removed by filtration and the organic phase was concentrated under vacuum. The crude product was purified by silica gel column chromatography using ethyl acetate/hexane mixed solvent as elution system. | [References]
[1] Farmaco, Edizione Scientifica, 1986, vol. 41, # 10, p. 794 - 800
[2] Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999), 1997, p. 449 - 462
[3] European Journal of Medicinal Chemistry, 2009, vol. 44, # 2, p. 809 - 817
[4] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 6, p. 527 - 531
[5] European Journal of Medicinal Chemistry, 2016, vol. 108, p. 334 - 346 |
|
|